banner

News Releases

Date Title and Summary  
Toggle Summary ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
- First-in-class, non-opioid, mechanism interrupts pain pathways - Phase 2 initiation planned for the first half of 2021 SAN DIEGO & FORT WORTH, Texas --(BUSINESS WIRE)--Aug. 25, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need SAN DIEGO & MELBOURNE, Australia --(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
- ACADIA acquires exclusive worldwide rights to a novel therapeutic program targeting muscarinic M1 receptors SAN DIEGO & NASHVILLE, Tenn. --(BUSINESS WIRE)--May 7, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Vanderbilt University today announced an exclusive worldwide license agreement
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
- The study did not achieve statistical significance on the primary endpoint - Conference call and webcast to be held today at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- If approved, NUPLAZID would be the first and only treatment indicated for dementia-related psychosis - Prescription Drug User Fee Act (PDUFA) date set for April 3, 2021 - Conference call and webcast to be held today at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Gudarz Davar as Executive Vice President and Head of Research and Development. Dr. Davar will be responsible for leading research and development activities at ACADIA and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
SAN DIEGO --(BUSINESS WIRE)--May 28, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
- 1Q20 Net Sales of $90.1 Million , a 43% Increase Over 1Q19 - On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer - Announced worldwide license agreement and collaboration with Vanderbilt University for new central nervous system
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
- Full Year 2019 Net Sales Grew to $339.1 Million , a 52% Increase over Full Year 2018 - 2020 Net Sales Guidance of $440 to $470 Million - On-Track to Submit Supplemental New Drug Application for Dementia-Related Psychosis in Summer 2020 SAN DIEGO --(BUSINESS WIRE)--Feb.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
- 2Q20 Net Sales of $110.1 Million , a 32% Increase Over 2Q19 - FDA filed the supplemental NDA for pimavanserin for the treatment of dementia-related psychosis with a PDUFA action date set for April 3, 2021 - Initiated ADVANCE-2, a Phase 3 study evaluating pimavanserin for the treatment of the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- Submission based on positive results from the Phase 3 HARMONY study which showed a statistically significant 2.8 fold reduction in the risk of relapse of psychosis SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
ACADIA to Host Conference Call and Webcast on Thursday, May 7, 2020 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 15, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020 , after the close of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
ACADIA to Host Conference Call and Webcast on Wednesday, February 26, 2020 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 12, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2020 , at 4:30 p.m. Eastern Time   SAN DIEGO --(BUSINESS WIRE)--Jul. 22, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020 , after the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
- Top-line results expected in 3Q20 SAN DIEGO --(BUSINESS WIRE)--May 26, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
SAN DIEGO --(BUSINESS WIRE)--Jan. 7, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
SAN DIEGO --(BUSINESS WIRE)--Feb. 24, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40 th Annual Health Care Conference in Boston on Monday, March 2, 2020 , at 2:10 p.m. Eastern Time . A live webcast of ACADIA’s presentation will be
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
SAN DIEGO --(BUSINESS WIRE)--Jun. 2, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41 st Annual Global Healthcare Conference on Tuesday, June 9, 2020 , at 4:40 p.m. Eastern Time . The conference will be held virtually.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
SAN DIEGO --(BUSINESS WIRE)--Aug. 12, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020 , at 11:00 a.m. Eastern Time . The conference will be held virtually.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--May 5, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences: 2020 BofA Securities Health Care Conference on Tuesday, May 12, 2020 , at 11:00 a.m. Eastern Time .
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Sep. 2, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences: Citi 15th Annual BioPharma Virtual Conference Date: Wednesday, September 9, 2020 Panel: Emerging Therapies for
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
SAN DIEGO --(BUSINESS WIRE)--May 21, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020
Printer Friendly Version
Toggle Summary People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
- Key findings presented at AAIC 2020 include: a need to improve patients’ symptoms and ability to know what is real versus what is not real - When asked to rank the impact on their own life, patients reported that visual hallucinations were the most impactful symptom - Care partners reported
Printer Friendly Version